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ABSTRACT
Vam3 is a SNARE protein essential in yeast vacuole homotypic fusion. The specific role of
the Vam3 trans-membrane domain (TMD) during vacuole fusion remains unclear. Previous work
had shown that replacing Vam3 TMD with a prenyl lipid anchor (CCIIM) results in attenuated
fusion and accumulation of trans-SNARE complexes, indicating CCIIM can not transit enough
energy to stimulate membrane fusion as Vam3 TMD does. Hypothesis were proposed that the
either the length or the specific Vam3 TMD interactions with its cognate SNAREs, or a
combination of both, result in the less efficient fusion with Vam3-CCIIM. In this study, I further
studied the Vam3-CCIIM vacuole fusion and vacuole morphology. To test the above hypotheses,
I constructed truncations at the C-terminus of the Vam3 TMD to study the effect of varying
length of Vam3 TMD. To study the specific TMD interactions with other SNAREs, I mutated
three non-aliphatic amino acids in the Vam3 TMD that may contribute to inter-helical
interactions with cognate SNAREs. I also constructed the yeast mutant strains and found those
mutations cause vacuole fragmentation. These mutants could be used for further studying their
effect on fusion and protein complex formation, and deciphering Vam3 TMD's role during
fusion.
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1Chapter 1 Introduction
1.1 Yeast Vacuole Fusion
Membrane fusion is critical for maintaining cellular homeostasis, subcellular
compartmnetalization, cell growth, hormone secretion and the release of neurotransmitters (1).
The machinery for membrane fusion was found to be conserved from single-cellular eukaryotes,
such as yeast, to evolutionarily more advanced mammals (2).
Yeast vacuole homotypic fusion is widely used as a model system for the study of membrane
fusion because genetic manipulation in yeast is much easier than that in higher eukaryotes like
mice. Moreover, yeast vacuoles are large organelles whose morphology can be well examined
under a light microscope. Yeast vacuoles can also be readily harvested in large quantities,
facilitating high-throughput experiments. Furthermore, a rapid and convenient in vitro
colorimetric assay has been developed to measure the fusion of yeast vacuoles since purified
vacuoles bear a full set of all the molecules necessary for fusion. Experiments that can
reconstitute all-pure components in fusion are well established as well (1, 3).
Yeast vacuole fusion requires close cooperation of the following components: four SNARE
proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptors), which include
Nyv1, Vam3, Vti1, and Vam7, and their chaperones Sec18/NSF and Sec17/α-SNAP, a Rab
family GTPase Ypt7, the hexameric tethering complex HOPS (homotypic fusion and protein
sorting complex), composed of Vps11, Vps16, Vps18, Vps33, Vps39 and Vps41 as its 6 subunits,
actins, and five regulatory lipids including ergosterol, phosphatidic acid, diacylglyerol,
sphingolipids and phosphoinositides (4, 5, 6).
Vacuole fusion occurs on four steps: priming, tethering, docking and vertex assembly,
hemifusion and fusion. During priming, cis-SNAREs (SNARE proteins on the same side of the
2membrane) are disassembled by Sec18, releasing Sec17 (7), free SNAREs and soluable Vam7
(8). Next, the first molecular association between the two membranes that are about to fuse,
termed 'tethering', is Ypt7 dependent (9, 10). Soluble Vam7 rebind to the membrane by the
interaction between its PX domain and HOPS and phosphatidylinositol 3-phosphate (PI3P) on
the membrane (9, 11). Next, SNARE proteins bind to each other forming SNARE complexes in
trans (between two membranes) that triggers the releasing of luminal calcium (12, 13). The
resulting tight association between docked vacuoles lead to the formation of two flattened discs
of the two apposed membranes called boundary membranes. The perimeters of the boundary
membranes are termed 'vertex ring' where proteins and regulatory lipids important in vacuole
fusion are concentrated (14). With the completion of fusion, not only the lipid bilayers, but also
the luminal content of the two vacuoles mix together.
First discovered in late 1980s, SNARE proteins are found crucial in membrane fusion, with
their significance implicated by the fact that they are found in all organelles of exocytic and
endocytic pathways, from yeast to man (15, 16). With several exceptions, most SNARE proteins
are composed of a variable and independently-folded N-terminal domain, a coiled-coil SNARE
motif and a C-terminal trans-membrane domain which functions as the membrane anchor. The
SNARE motif is characteristic of SNARE proteins and is evolutionarily conserved (15). SNARE
complexes formation is mediated by SNARE motifs, which can spontaneously associate into a
four-helix bundle, with each helix provided by a different SNARE motif (17). The free energy
released during SNARE complexes formation by SNAREs from opposite membranes leads to a
tight connections between the opposing membranes and is thought to drive the membranes to
fuse, resulting in trans-SNARE complexes converting to cis-SNARE complexes. The residues in
the SNARE motifs are generally apolar, but the '0'-layer near the center of the 4-helix bundle are
polar, composed of highly conserved 3 glutamine (Q) and 1 arginine (R) (18, 4). SNAREs are
3then classified into Qa-SNAREs, Qb-SNAREs, Qc-SNAREs and R-SNAREs. Productive
SNARE complexes requires the four-helix bundle formation by SNARE motifs from one of each
of the Qa-, Qb-, Qc- and R-SNAREs (15). Vam3, Vti1 and Vam7 are the Qa-, Qb-, Qc-SNAREs
and Nyv1 is the one R-SNARE in yeast homotypic vacuole fusion. Though most SNARE
complexes have the QabcR combination, SNARE motifs can potentially associate in other
combinations, such as Qaaaa complexes, Qabab complexes, Qaabc complexes. Thesse helical
bundles with non-conventional combinations are less stable, and might not have the correct
membrane topology, and are less capable of transit the energy to drive membrane fusion (15, 19,
20). Finally, after fulfilling their role in driving membrane fusion, SNARE complexes can be
disassembled and recycled by Sec18/NSF and Sec17/α-SNAP in an ATP-dependent manner
during the initial priming step of the next round of fusion.
1.2 Vam3
Vam3 is a 283-amino-acid-long protein. It has three N-terminal regulatory alpha helical
domains (HA, HB and HC, respectively), the SNARE motif, and the C-terminal helical
trans-membrane domain (TMD).
Vam3 is essential for yeast homotypic vacuole fusion. Being a Qa-SNARE, Vam3 associates
with Vam7, Vti1 and Nyv1 to form the four helix bundle with its SNARE motif to catalyze
fusion.Vacuoles lacking Vam3 can not fuse normally (21, 22). Though the alpha-helical TMD of
Vam3 was previously shown to be critical for productive priming and normal fusion (22), the
specific mechanism of Vam3 trans-membrane domain during fusion remains unclear. Ungermann
and colleagues made a Vam3-CCIIM chimera in which the trans-membrane domain of Vam3
protein was replaced by the prenylation motif from Ykt6. Vam3-CCIIM was localized to
4vacuoles and expressed at levels comparable to wild-type Vam3 expression levels. However,
fusion of Vam3-CCIIM was strongly attenuated, and had an increased amount of cis-SNARE
complexes, indicating that Sec18-dependent priming and cis-SNARE complex disassenbly was
attenuated. In fact, efficient cis-SNARE complex disassembly requires addition of exogenous
Sec18. There is also an 4-fold increase in the amount of trans-SNARE complexes, indicating that
Vam3-CCIIM cannot transit enough energy to stimulate membrane fusion and converting
trans-SNARE complexes to cis-SNAREcomplexes. Furthermore, there is a 50% decrease in the
palmitoylation of Vac8, which is required during early stages of priming (22).
The accumulation of trans-SNARE complexes containing Vam3-CCIIM indicates that the
prenyl anchor CCIIM could not transit sufficient energy to the membranes to initiate fusion as
the native Vam3 TMD can. Two hypothesis were proposed to explain it: first, lipid anchors only
cross one leaflet of the membrane bilayer, so less energy could be transited through the lipid
anchor than through the longer native Vam3 CCIIM. The alternative hypothesis is that the native
Vam3 TMD has specific interactions with cognate SNAREs and changing it to a lipid anchor
affects the formation of productive SNARE complexes, resulting in the inability for
trans-SNARE complexes to trigger fusion. The second hypothesis is supported by several
neuronal SNAREs studies. A structural study of the neuronal cis-SNARE complexes indicated
that the alpha-helical bundle proceed beyond the SNARE motifs and continues into the linker
region (a short region between the SNARE motif and the C-termianl TMD) and the TMD. It's
noted that the continuous helical bundle is further stabilized by side-chain interactions in the
linker region. It's unknown, however, whether the bundling of TMDs is important or whether
there are any specific interactions between the TMDs of cognate vacuolar SNAREs (23).
Another group found that truncated or deleted TMD of syntaxin have reduced binding affinities
with synaptotagmin, α/β-SNAP, and synaptobrevin. Normal cognate protein binding could be
5"rescued" by replacing the TMD of syntaxin with TMD of synaptobrevin and synaptotagmin.
However, normal binding could not be rescued by fuse TMD-deleted syntaxin with TMD of
other hydrophobic amino acids of the same length (1124). These findings strongly suggest the
shorter length of CCIIM could not be the only reason for Vam3-CCIIM to fuse poorly, and it's
most likely that both the length and specificity of SNARE TMD interactions contribute to
efficient fusion.
Moreover, Vam3 trans-membrane domain can form homodimers via the TMD-TMD
interactions (25). Replacing the native Vam3 TMD with a stretch of polyalanine disrupted the
dimerization (25). Mutations that would disrupt dimerization of TMD of syntaxin won't impair
the full-length syntaxin's binding with other cogante SNAREs, indicating a poor correlation
between Vam3 TMD homodimerization and bundling of SNARE TMDs.
In order to further study the function of Vam3 trans-membrane during fusion and decipher
the mechanism of attenuated fusion of Vam3-CCIIM, I constructed a series of mutants to test the
two hypothesis as stated above. To test the first hypothesis, I truncated Vam3 TMD which can be
used to test the effect of varying lengths of Vam3 TMD. To test the second hypothesis, I mutated
several non-aliphatic amino acid sites in Vam3 TMD that could contribute to inter-helical
interactions with other cognate SNAREs. These sites include an N-terminal T266, and
C-terminal C274 and M275. I mutated each of these residues to alanine, and constructed a
mutant containing all three mutations (Vam3-3Ala). I further constructed the mutant yeast strains,
which can be used for studying their effect on fusion and protein complex formation.
6Chapter 2 Materials and Methods
2.1 Strains
Yeast strains BJ Vam3-CCIIM (MATα pep4::HIS3 prb1-Δ1.6R his3-200 lys2-801 trp1Δ101
(gal3) ura3-52 gal2 can1 Δ vam3Δ VAM3CCIIM::URA3) and DKY Vam3-CCIIM (MATα
pho8::TRP1 leu2-3 leu 2-112 ura3-52 his3-Δ200 trp1-Δ901 lys2-801Δ vam3Δ
VAM3CCIIM::URA3) were used for the study of Vam3-CCIIM vacuole fusion and vacuole
morphology. Yeast strains BJ3505 (MATα pep4::HIS3 prb1-Δ1.6R his3-200 lys2-801 trp1Δ101
(gal3) ura3-52 gal2 can1) and DKY6281 (MATα pho8::TRP1 leu2-3 leu 2-112 ura3-52
his3-Δ200 trp1-Δ901 lys2-801) were used as wild-type controls in vacuole fusion assay,
microscopy analysis of vacuole fusion, colony PCR and Western blot.
CBP-Vam3 were cloned from yeast strain CBP-Vam3 (MATa pho8::TRP1 leu2-3 leu 2-112
ura3-52 his3-Δ200 trp1-Δ901 lys2-801). Mutant Vam3 plasmids were transformed into the
following yeast strains: BJ ΔVam3 (MATa pep4::HIS3 prb1-Δ1.6R his3-200 lys2-801 trp1Δ101
(gal3) ura3-52 gal2 can1 vam3Δ) and DKY ΔVam3 (MATa pho8::TRP1 leu2-3 leu 2-112
ura3-52 his3-Δ200 trp1-Δ901 lys2-801 vam3Δ).
2.2 Vacuole Isolation and Fusion Assays
Yeast vacuoles were isolated by floatation with four-tiered ficoll gradient after the yeast cell
wall were broken down by lyticase. Large amounts of vacuole could be isolated and purified in
this way, and the amount of the vacuoles were quantified with a Bradford assay (26).
In vitro fusion reactions (30 μl) contained 3 µg with each of vacuoles from or derived from
BJ3505 and DKY6281, fusion buffer (125 mM KCl, 5 mM MgCl2, 20 mM PIPES-KOH pH 6.8,
200 mM Sorbitol), ATP regenerating system (1 mM ATP, 0.1 mg/ml creatine kinase, 29 mM
7creatine phosphate), 10 µM coenzyme A, 283 nM inhibitor of protease B (IB2). The reactions
were incubated at 27°C for 1.5 hours, after which fusion was assayed by Pho8 activity in 250
mM Tris-HCL pH 8.5, 0.4% Triton X-100, 10 mM MgCl2, 1 mM p-nitrophenylphosphate. One
fusion units were measured as 1 µmol of p-nitrophenolate produced minute – 1, µg – 1 pep4Δ
vacuoles. p-nitrophenolate absorbance was measured at 400 nm (27).
2.3 Molecular Cloning and Site-Directed Mutagenesis of CBP-Vam3
The CBP-Vam3 open reading frame was amplified from CBP-Vam3 yeast strains, using
forward primer 5'-GCTGCGAAGCTTATGTCCTTTTTCGACATC-3' with a HindIII restriction
site, and a reverse primer 5'-GCGGCCGGATCCCTAACTTAATACAGCAAG-3' with a BamHI
restriction site. Digested PCR product was ligated to HindIII/BamHI-digested pRS416 to
generate pRS416-CBP-Vam3p. The plasmid was transformed into Escherichia coli Turbo high
efficiency competent cells (NEB) and grown on Luria broth with ampicillin. The plasmids
re-isolated from the colonies was verified by dideoxynucleotide chain-termination sequencing.
With pRS416-CBP-VAM3 being the template, a modified version of QuickChange
mutagenesis were used to generate Vam3T266A, Vam3C274A, Vam3M275A, Vam3C274A/M275A, and
Vam3T266A/C274A/M275A. The primers for mutating these targeted sites contains a non-overlapping
sequences at the primers 3' end as well as the conventional primer-primer overlapping sequences
at the 5' end to minimize the primer dimer formation and enable the primers to use the
newly-synthesized DNA as the template, thus promote the efficiency of site-directed mutagenesis
(28). Since C274 and M275 are next to each other, I mutated both these sites during one round of
mutagenesis using one pair of primers carrying both mutations. Primer used for mutating these
sites are listed in Table 2. The primers were synthesized from Integrated DNA Technologies
8(1710 Commercial Park, Coralville, Iowa 52241 USA). All the mutants were sequenced by
ACGT, Inc. (35 Waltz Drive, Wheeling, IL 60090) and verified.
2.4 Construct of Vam3 Mutant Yeast Strains
To construct Vam3 mutant yeast strains, each of the mutant Vam3 plasmids, Vam3T266A,
Vam3C274A, Vam3M275A and Vam3T266A/C274A/M275A, were transformed into both BJ ΔVam3 and
DKY ΔVam3 yeast strains, respectively, and grown on selective medium lacking uracil and
containing ampicillin as the selection marker. Colonies grew after about 4 days, and no colonies
grew for the negative control plates (BJ ΔVam3 and DKY ΔVam3 competent cells not
transformed with mutant Vam3 plasmids). Yeast colony PCR and Western blot were used to
verify the transformation.
2.5 Microscopy
Vacuole morphology was monitored as described (29). Incubate yeast cells with 5 µM
FM4-64 fluorescent dye labeling yeast vacuolar membranes for one hour. Cells were then
washed and continued grown for over 3 hours. Next, cells were washed with PBS buffer,
concentrated, and mixed with poly-L-lysine and spread on glass slides for observation. Images
were obtained with a Zeiss Axio Observer Z1 inverted fluorescent microscope equipped with an
X-Cite 120XL light source, Plan Apochromat 63X oil objective and an AxioCam CCD camera.
FM4-64 images were obtained with a 43 HE CY 3 shift-free filter set.
2.6 Vam3 Truncations
To generate a series of truncations of Vam3 in its C-terminal trans-membrane domain, the
9Vam3 open reading frame, excluding last 3, 5, 7, 9 amino acid residues in the trans-membrane
domain were amplified from DKY6281 yeast strains. The primers used were listed in Table 2.
The forward primers carry a HindIII restriction site, and the reverse primers carry a EcoRI
restriction site. Digested PCR products were then ligeated into double-digested pRS416 and
transformed into Escherichia coli Turbo high efficiency competent cells (NEB) and grown on
Luria broth with ampicillin. The plasmids re-isolated from the colonies was verified by
dideoxynucleotide chain-termination sequencing.
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Chapter 3 Results
3.1 Vam3-CCIIM
3.1.1 Vam3-CCIIM Vacuole Fusion Assay
Fusion was measured by the maturation of proPho8p (pro-alkaline phosphatase) by protease
A (Pep4p) (29). These experiments used vacuoles from reciprocally deleted stranis
DKY6281(PEP4 pho8Δ) and BJ3505 (pep4Δ PHO8). Previous study showed that Vam3-CCIIM
fuses poorly, showing an 80% reduction in fusion relative to WT vacuoles (22). Previous work in
our lab showed that fusion blocked by anti-Sec17 at the priming step can be bypassed by adding
exogenous Vam7 as they can form SNARE complexes with free cognate SNAREs on the
membrane and therefore fusion can go on (16). I used different combinations of vacuoles to
repeat the Vam7 bypass fusion assays. One combination used WT and Vam3-CCIIM vacuoles at
a 1:1 ratio, where the DKY6281 reporter strain contained WT Vam3 and the BJ3505 reporter
strain harbored Vam3-CCIIM. Another combination used BJ3505 containing WT Vam3 and
DKY6281 harbouring Vam3-CCIIM. A third combination used both reporter strains that
harbored Vam3-CCIIM. For all of them, fusion could be inhibited by anti-Sec17, but could not
be rescued by adding exogenous Vam7 alone. CPZ was used to see if fusion could be restored.
CPZ is a small amphipathic molecule that can traverse the lipid bilayer and insert itself into the
inner leaflet of membranes, and can therefore increase the negative curvature of the outer leaflet
of the bilayer, believed to reduce the energy threshold for SNAREs-driven membrane fusion (30).
For the first two combinations, where Vam3-CCIIM is only present on one side of the vacuoles
and WT Vam3 is present on the other side of the vacuoles, fusion could be restored by adding
CPZ. However, for the combinations where both strains harboured Vam3-CCIIM, CPZ is unable
to restore fusion. Several Vam7 mutants, including Vam7Q283R, Vam7Y42A, Vam7 ΔCC, were able
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to rescue fusion in the presence of CPZ, with WT DKY and Vam3-CCIIM BJ vacuoles, though
to less extents (Figure 1).
3.1.2 Vam3-CCIIM Vacuole Morphology
Since Vam3-CCIIM affect yeast vacuole fusion, it's possible that Vam3-CCIIM would affect
vacuole morphology. To examine the its vacuole morphology, DKY Vam3-CCIIM yeast cells
were incubated with 5 µM FM4-64 to label vacuoles. Cells were washed with PBS and grown
for another 3 hours before mounted in poly-L-lysine for microscopy. Cells were photographed
using DIC, and FM4-64 images were acquired using a 43 HE CY 3 shift-free filter set (29).
DKY6281 (wild-type) were used as positive control and DKYΔVam3 were used as negative
control. Previously, Vam3-CCIIM strains were shown to have a single large intact vacuole in
each cell (22). However, I observed cells both harbouring large intact vacuoles, and small
amounts of cells harbouring multiple or even fragmentted vacuoles in Vam3-CCIIM (Figure 2.1).
After careful observation, quantification and statistical analysis of the number of vacuoles per
cell in each cell type, it's observed that approximately 60% of Vam3-CCIIM cells harbouring a
single vacuole per cell, while the rest of the cells may have 2, 3, 4, 5 or more fragemented
vacuoles per cell. Most wild-type cells harhour a single intact vacuole per cell, while most of the
ΔVam3 cells have over 3 vacuoles per cell. So, Vam3-CCIIM's phenotype is an intermediate
between that of wildtype and that of the deletion strain, indicating that Vam3-CCIIM is
functional in vivo, though the functionality is impaired in comparison with the wild-type Vam3.
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3.2 Vam3 TMD Mutations
3.2.1 Vam3 TMD Site-Directed Mutagenesis
First, CBP-Vam3 were cloned from CBP-Vam3 yeast strains as a template for mutagenesis.
The calmodulin binding peptide (CBP) tag can facilitate future protein interaction study by
CBP-pulldown assay. The CBP-Vam3 open reading frame was amplified from CBP-Vam3 yeast
strain, using forward primer 5'-GCTGCGAAGCTTATGTCCTTTTTCGACATC-3' with a
HindIII restriction site, and a reverse primer
5'-GCGGCCGGATCCCTAACTTAATACAGCAAG-3' with a BamHI restriction site (Table 2.).
Digested PCR product was ligated to HindIII/BamHI-digested pRS416 to generate
pRS416-CBP-Vam3p. The plasmid was transformed into Escherichia coli Turbo high efficiency
competent cells (NEB) and grown on Luria broth with ampicillin. The plasmids re-isolated from
the colonies was verified by dideoxynucleotide chain-termination sequencing.
With pRS416-CBP-VAM3 being the template, I mutated T266, C274 and M275 to in the
TMD of Vam3 to alanine. The three mutation sites were shown in Figure 3. A modified version
of QuickChange mutagenesis protocol were used, which is more efficient than the conventional
QuickChange protocol, with the success rate being approximately 25%. The primers for mutating
these targeted sites contains a non-overlapping sequences at the primers' 3' end as well as the
conventional primer-primer overlapping sequences at the 5' end to minimize the primer dimer
formation and enable the primers to use the newly-synthesized DNA as the template, thus
promote the efficiency of site-directed mutagenesis (28). Primer used for mutagenesis are listed
in Table 2.
Creating the three single mutants (Vam3T266A, Vam3C274A, Vam3M275A) were relatively quite
easy, and were successful in the first two attempts. Since C274 and M275 are next to each other,
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I then mutated both these sites during one round of mutagenesis using one pair of primers
carrying both mutations. As mutating two sites at the same time causes more mismatches
between the primers and the template, lower annealing temperature and less stringent conditions
were used in the polymerase chain reaction (PCR). I also picked more colonies and sent more
plasmids for sequencing. Vam3C274A/M275A were successfully created, though the mutagenesis
success rate were slightly lower.
For creating Vam3T266A/C274A/M275A triple mutant, C274 and M275 were mutated on the
pRS416-CBP-VAM3T266A template. Several attempts were made before the triple mutant were
obtained. Initially, the primer used were so long, though it carries C274A and M275A mutations,
spans over T266 as well and unintentionally back mutate T266A to threonine. New primers were
designed, with alanine at T266 site. Back mutations were avoided and Vam3T266A/C274A/M275Awere
made.
All the mutants, including Vam3T266A, Vam3C274A, Vam3M275A, Vam3C274A/M275A, and
Vam3T266A/C274A/M275A ,as described above were verified by sequencing.
3.2.2 Vam3 Mutants Yeast Strains Construction
To construct Vam3 mutant yeast strains, each of the mutant Vam3 plasmids, Vam3T266A,
Vam3C274A, Vam3M275A and Vam3T266A/C274A/M275A, were transformed into both BJ ΔVam3 and
DKY ΔVam3 yeast strains, respectively, and grown on selective medium lacking uracil and
containing ampicillin as the selection marker. After that, yeast genomic DNA were isolated from
colonies of each of the new strains, and PCR using primers from upstrem and downstream of
Vam3 open reading frame (CBP-Vam3-F and CBP-Vam3-R, as listed in Table 2) were performed
to see if the transformation were successful. BJ3505 and DKY6281 were used as positive
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controls and BJ ΔVam3 and DKY ΔVam3 were used as negative controls. The first several
attempts were unsuccessful, as Vam3 DNA fragments were amplified not only from the
transformed strains and positive controls, but also from BJ ΔVam3 and DKY ΔVam3. Different
pairs of Vam3 primers were used in PCR with similar results. It's probable that the BJ ΔVam3
and DKY ΔVam3 yeast stock contained a mixture of wild-type and Vam3-deletion cells. So I
spread BJ ΔVam3 and DKY ΔVam3 in uracil-dropout plates and picked single colonies, and use
them as starting points for transformation.
After transformation, colonies grew after about 4 days, and no colonies grew for the
negative control plates (BJ ΔVam3 and DKY ΔVam3 competent cells not transformed with
mutant Vam3 plasmids). These colonies were verified by PCR. Yeast colony PCR, instead of
isolating genomic DNA and using genomic DNA as the template to perform PCR, were used to
accelerate the project. Vam3 could be amplified from BJ ΔVam3 and DKY ΔVam3 transformed
with mutant Vam3 plasmids, and no Vam3 were amplified from BJ ΔVam3 and DKY ΔVam3
deletion strains (Figure 4). It's also noted that the size of Vam3 amplified from wild-type BJ3505
and DK6281 were slightly smaller than that from the deletion strains transformed with mutant
Vam3 plasmids. It's consistent with the fact that mutant Vam3 plasmids carry a small CBP tag.
The sequence coding CBP tag is about 50 bp. The yeast colony PCR results indicate that
Vam3T266A, Vam3C274A, Vam3M275A and Vam3T266A/C274A/M275A were successfully transformed into
BJ ΔVam3 and DKYΔVam3 yeast strains, and Vam3 mutant yeast strains were created.
3.2.3 Vam3 Mutants Vacuole Morphology
The same method for observing Vam3-CCIIM vacuole morphology were used to observe
DKY Vam3T266A, Vam3C274A, Vam3M275A, and Vam3T266A/C274A/M275A vacuole morphology. DKY
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ΔVam3 were used as negative controls, and the DKY6281 were used as positive controls. Each
type of Vam3 mutant cells contained fragmented and deformed vacuoles (Figure 5.1). A
statistical analysis were made to quantify the number of vacuoles per cell for each cell
type(Figure 5.2). Almost all wild-type cells contain a single vacuole per cell, and ΔVam3 cells
are highly fragmented cells. Over 90% of DKY Vam3T266A, Vam3C274A, Vam3M275A, and
Vam3T266A/C274A/M275A cells were fragmented, but they have a higher proportion of cells containing
one of two vacuole per cell than ΔVam3 cells. It's also noted that most yeast vacuoles has a
diameter of 5-6.5 µm, while in BJ Vam33Ala extraordinarily large vacuole with a diameter of 9-10
µm were observed (Figure 5.3).
3.3 Vam3 TMD Truncations
In order to study the effect of varying lenght in Vam3 TMD, a couple of truncations in the
C-terminal of the TMD were made.The plasmids were made by amplifying the Vam3 open
reading frame, excluding last 5, or 9 amino acid residues in the trans-membrane domain from
DKY6281 yeast strains. The primers used were listed in Table 2. The forward primers carry a
HindIII restriction site, and the reverse primers carry a EcoRI restriction site. Digested PCR
products were then ligeated into double-digested pRS416 and transformed into Escherichia coli
Turbo high efficiency competent cells (NEB) and grown on Luria broth with ampicillin. The
plasmids re-isolated from the colonies was verified by dideoxynucleotide chain-termination
sequencing.
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Chapter 4 Discussion
4.1 Vam3-CCIIM
Vam3-CCIIM vacuoles fuse poorly compared to the wild-type, indicating the importance of
Vam3 trans-membrane domain in yeast vacuole fusion. For wild-type Vam3, blocked the priming
stage with anti-Sec17 could be bypassed by adding exogenous Vam7p. However, Vam3-CCIIM
on one side or both sides of the vacuoles cannot promote fusion in Vam7 bypass fusion assays.
By adding CPZ, fusion could be restored when Vam3-CCIIM is present on one side of the
vacuoles, but fusion could not be restored when both sides of the fusion pairs carry Vam3-CCIIM.
It suggest that wild-type Vam3 on one side of the vacuole is capable of transit sufficient energy
to drive fusion, with the help of CPZ. When Vam3 is absent on both sides of vacuoles,
Vam3-CCIIM cannot generate and transit sufficient energy for fusion.
Most Vam3-CCIIM cells harbouring a single vacuole, but there is a sharp increase in cells
harbouring multiple vacuoles. It suggests that Vam3-CCIIM is able to function in vivo, but this
functionality is somewhat impaired.
4.2 Vam3 TMD Mutations
In order to study the specific interactions between the Vam3 TMD with the TMDs of cognate
SNAREs, a mutational study was made. Three non-aliphatic amino acids in the Vam3 TMD that
could contribute to inter-helical interactions with other cognate SNAREs were mutated to alanine.
These sites include an N-terminal T266, and C-terminal C274 and M275. Using
pRS416-CBP-VAM3 as the template, Vam3 TMD mutations including Vam3T266A, Vam3C274A,
Vam3M275A a, Vam3C274A /M275 and Vam3T266A/C274A/M275A were constructed. The corresponding
mutant yeast strains were obtained by transformation and verified by colony PCR. These mutants
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causes vacuole fragmentation, indicating impaired functionality in vivo. BJ Vam3T266A/C274A/M275A,
in particular, showed sporadic extraordinarily large vacuoles. The abnormally large vacuoles may
result from changed homeostasis and membrane fusion. Though the possibility that they're due to
altered physiological status of that specific strain could not be excluded at present. All the
mutants, especially Vam3T266A/C274A/M275A could be used in experiments like CBP-pulldowns,
vacuole fusion assays, etc, to determine their effect on protein complex formation and fusion,
and shed light on the specificity of Vam3 TMD interactions. The pRS416-CBP-VAM3 I
constructed could be used as a template to generate other Vam3 mutations if needed. Moreover,
there is little mutational analysis in the transmembrane domain of other SNAREs. Two polar
residues at S197 and Y198 in the TMD of Vti1, and S244 in the TMD of Nyv1 may be critical in
the interaction between SNARE TMDs. The same method of constructing Vam3 mutants is
applicable to create Vti1S197A, VtiY198A and Nyv1S244A.
4.3 Vam3 TMD Truncations
To examine the effect of varying lengths of the Vam3 TMD, a couple of Vam3 TMD
truncations were created. In the future, corresponding yeast strains will be generated and their
effect on SNARE complex formation, priming and fusion will be examined. If fusion is
significantly reduced in Vam3 TMD truncations, the length of the Vam3 TMD is a major factor
for its function in fusion, and the impaired fusion in Vam3-CCIIM should be at least partially
attributed to the shorter length of the lipid anchor. If fusion is unaltered in Vam3 TMD, the
second hypothesis is more likely to be correct.
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Tables and Figures
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Table 1. Yeast strains used in this study
Strain Genotype Source
BJ3505 MATα pep4::HIS3 prb1-Δ1.6R his3-200 lys2-801 trp1Δ101 (gal3) ura3-52 gal2 can1 Jones
DKY6281 MATα pho8::TRP1 leu2-3 leu 2-112 ura3-52 his3-Δ200 trp1-Δ901 lys2-801 Klionsky
BJ Vam3-CCIIM BJ3505, vam3Δ VAM3CCIIM::URA3 Ungermann
DKY Vam3-CCIIM DKY6281, vam3Δ VAM3CCIIM::URA3 Ungermann
CBP-Vam3 DKY6281, vam3Δ CBP-VAM3::URA3 Wickner
BJ ΔVam3 BJ3505 vam3Δ Wickner
DKYΔVam3 DKY6281 vam3Δ Wickner
BJ Vam3T266A BJ3505, vam3Δ VAM3T266A::URA3 This Study
BJ Vam3C274A BJ3505, vam3Δ VAM3C274A::URA3 This Study
BJ Vam3M275A BJ3505, vam3Δ VAM3M275A::URA3 This Study
BJ Vam33A BJ3505, vam3Δ VAM3T266A/C274A/M275A::URA3 This Study
DKY Vam3T266A DKY6281, vam3Δ VAM3T266A::URA3 This Study
DKY Vam3C274A DKY6281, vam3Δ VAM3C274A::URA3 This Study
DKY Vam3M275A DKY6281, vam3Δ VAM3M275A::URA3 This Study
DKY Vam33A DKY6281, vam3Δ VAM3T266A/C274A/M275A::URA3 This Study
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Table 2. Primers used in this study
Purpose Primers Sequences
Cloning CBP-Vam3 CBP-Vam3-F 5'-GCTGCGAAGCTTATGTCCTTTTTCGACATC-3'
CBP-Vam3-R 5'-GCGGCCGGATCCCTAACTTAATACAGCAAG-3'
Mutagenesis Vam3T266A-F 5'-GGTCGCCCTAATCATTATAATAGTTGTGTGCATGGTGGTATTG-3'
Vam3T266A-R 5'-TTATAATGATTAGGGCGACCTTACCGCATTTGTTACGGTC-3'
Vam3C274A-F 5'-AGTTGTGGCCATGGTGGTATTGCTTGCTGTATTAAGTTAG-3'
Vam3C274A-R 5'-ACCATGGCCACAACTATTATAATGATTAGGGTGACCTTACCG-3'
Vam3M275A-F 5'-AGTTGTGTGCGCGGTGGTATTGCTTGCTGTATTAAGTTAG-3'
Vam3M275A-R 5'-CCGCGCACACAACTATTATAATGATTAGGGTGACCTTACCG-3'
Vam3C274A/M275A-F 5'-AGTTGTGGCCGCGGTGGTATTGCTTGCTGTATTAAGTTAG-3'
Vam3C274A/M275A-R 5'-ACCGCGGCCACAACTATTATAATGATTAGGGTGACCTTACCG-3'
Truncations Vam3-F 5'-GCTGCGAAGCTTATGTCCTTTTTCGACATC-3'
Vam3-T2-R 5'-GCGGTCGAATTCCAATACCACCATGCACAC-3'
Vam3-T4-R 5'-GCGGCCGAATTCGCACACAACTATTATAATG-3'
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Figure 1. Vam3-CCIIM fusion assay. Three combinations of vacuoles were used for the fusion
assay. The first combination used Vam3-CCIIM on BJ vacuoles and WT Vam3 on DKY
vacuoles. The second used WT Vam3 on BJ vacuoles and Vam3-CCIIM on DKY vacuoles. The
third combination used Vam3-CCIIM on both BJ and DKY vacuoles. Reactions were treated
with buffer or anti-Sec17 to block priming. Bypassing the priming block was attempted with
Vam7, Vam7Q283R (Q283R), Vam7Y42A(Y42A), Vam7-ΔCC (ΔCC) in the presence or absence
of chlorpromazine (CPZ). A reaction treated on ice were the negative control.
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Figure 2.1. Vam3-CCIIM vacuole morphology. DKY Vam3-CCIIM Yeast cells were incubated
with 5 µM FM4-64 to label vacuoles. Cells were washed with PBS grown for another 3 hours
before mounted in poly-L-lysine for microscopy. Cells were photographed using DIC, and
FM4-64 images were acquired using a 43 HE CY 3 shift-free filter set. DKY6281 (wild-type)
were used as the positive control and DKYΔVam3 were used as the negative control.
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Figure 2.2. Quantification of the number of vacuoles per cell in Vam3-CCIIM. Vacuole
morphology of DKY6281 (wild-type), DKY Vam3-CCIIM and DKYΔVam3 were studied under
fluorescence microscope, and the number of vacuoles per cell in each cell type were quantified.
For each cell type, over 100 cells were counted, and the experiment was repeated for 3 times.
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Figure 3. Vam3 mutation sites. Vam3p has three N-terminal alpha helical domains (HA, HB and
HC, respectively), a SNARE motif, and the C-terminal trans-membrane domain (TMD). Three
non-aliphatic amino acid sites in Vam3 TMD, that could contribute to inter-helical interactions
with other cognate SNAREs were mutated to alanine in this study. These three sites, including an
N-terminal T266, and C-terminal C274 and M275, were shown in the graph.
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Figure 4. Verification of Vam3 mutant yeast strains by PCR. Vam3T266A, Vam3C274A,
Vam3M275A and Vam3T266A/C274A/M275A were transformed into BJ ΔVam3 and DKY ΔVam3 yeast
strains. Yeast colony PCR were performed to verify Vam3 mutant yeast strains. BJ3505 and
DKY6281 were used as positive controls and BJ ΔVam3 and DKYΔVam3 were used as negative
controls.
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Figure 5.1. Mutation in Vam3 causes vacuole fragmentation. Mutant Vam3p vacuole
morphology. Vam3 mutant cells were incubated with 5 µM FM4-64 to label vacuoles. Cells
were washed with PBS grown for another 3 hours before mounted in poly-L-lysine for
microscopy. Cells were photographed using DIC, and FM4-64 images were acquired using a 43
HE CY 3 shift-free filter set. DKY6281 (wild-type) were used as the positive control and DKY
ΔVam3 were used as the negative control.
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Figure 5.2. Quantification of the number of vacuoles per cell in mutant Vam3. Vacuole
morphology of DKY6281 (wild-type), DKY Vam3T266A, Vam3C274A, Vam3M275A, Vam33Ala and
DKYΔVam3 were studied under fluorescence microscope, and the number of vacuoles per cell
in each cell type were quantified. For each cell type, over 100 cells were counted, and the
experiment was repeated for 3 times.
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Figure 5.3. Occasional abnormally large vacuole of BJ Vam33Ala. Most yeast vacuoles has a
diameter of 5-6.5 µm, while occasionally extraordinarily large vacuole with a diameter of 9-10
µm were observed in BJ Vam33Ala.
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Figure 6. Vam3 mutation sites. Truncations of Vam3 TMD were generated to study the effect of
varying length of Vam3 TMD. The truncation sites were shown in the graph.
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